<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790178</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00041999</org_study_id>
    <nct_id>NCT01790178</nct_id>
  </id_info>
  <brief_title>Ultrasound in Muscle Biopsy</brief_title>
  <official_title>Outcomes of Ultrasound-guided Versus Blind Core Muscle Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the proposed study is to evaluate the clinical utility of muscle
      ultrasonography for improving the diagnostic yield and safety of core muscle biopsy. Our
      facility currently uses core (needle) biopsy to obtain muscle samples in patients 18 years
      old or older. Currently, there is no imaging tool used to guide the actual biopsy. As muscle
      biopsy is an invasive and potentially painful procedure, improving the diagnostic yield of
      this test is important.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Tissue Obtained</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>This data will be analyzed to determine if ultrasound guidance improves muscle yield (as measured by pathology determined volume and mass).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Receiving Diagnosis From Muscle Biopsy</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>The rate of achieving a specific final diagnosis in ultrasound guided muscle biopsies vs. unguided biopsies will be examined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Related to Muscle Biopsy</measure>
    <time_frame>Patient involvement limited to the time of biopsy; Records analyzed up to 10 months after biopsy</time_frame>
    <description>Data will be examined to determine if ultrasound guidance reduces the rate of adverse events in muscle biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Times Biopsy Needle Was Inserted to Obtain Biopsy Tissue</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>For &quot;core&quot; or &quot;needle&quot; biopsies, the physician passes the needle into the muscle until they feel that adequate tissue samples have been obtained. This outcome measure is the number of passes required in each study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Inadequate Biopsy Samples</measure>
    <time_frame>At time of pathology review</time_frame>
    <description>The presence of an inadequate sample was determined by the blinded pathologist reading the muscle biopsies. This reflects the sample having enough preserved muscle tissue for histologic analysis. It is separate from the number of participants receiving a diagnosis. A sample may be adequate, but non-diagnostic. Only one biopsy was performed in each patients, so the number of biopsies is the same as the number of participants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Myopathy</condition>
  <condition>Myositis</condition>
  <condition>Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Ultrasound Guided Biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guided biopsy will be used in all patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Ultrasound Guided Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
    <arm_group_label>Ultrasound Guided Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive subjects scheduled for a biopsy at our EMG laboratory will be asked if
             they would like to participate until a total of 40 participants are obtained.

        Exclusion Criteria:

          -  Age under 18 years.

          -  Inability to provide consent for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa D. Hobson-Webb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <results_first_submitted>August 1, 2016</results_first_submitted>
  <results_first_submitted_qc>September 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2016</results_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Myositis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ultrasound Guided Biopsy</title>
          <description>Ultrasound guided biopsy will be used in all patients.
Ultrasound: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
        </group>
        <group group_id="P2">
          <title>Non-Ultrasound Guided Group</title>
          <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ultrasound Guided Biopsy</title>
          <description>Ultrasound guided biopsy will be used in all patients.
Ultrasound: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
        </group>
        <group group_id="B2">
          <title>Non-Ultrasound Guided Group</title>
          <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1875" spread="19.8"/>
                    <measurement group_id="B2" value="55.375" spread="12.8"/>
                    <measurement group_id="B3" value="55.7" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amount of Tissue Obtained</title>
        <description>This data will be analyzed to determine if ultrasound guidance improves muscle yield (as measured by pathology determined volume and mass).</description>
        <time_frame>At time of biopsy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrasound Guided Biopsy</title>
            <description>Ultrasound guided biopsy will be used in all patients.
Ultrasound: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
          </group>
          <group group_id="O2">
            <title>Non-Ultrasound Guided Group</title>
            <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Tissue Obtained</title>
          <description>This data will be analyzed to determine if ultrasound guidance improves muscle yield (as measured by pathology determined volume and mass).</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.23"/>
                    <measurement group_id="O2" value="0.28" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Receiving Diagnosis From Muscle Biopsy</title>
        <description>The rate of achieving a specific final diagnosis in ultrasound guided muscle biopsies vs. unguided biopsies will be examined.</description>
        <time_frame>At time of biopsy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrasound Guided Biopsy</title>
            <description>Ultrasound guided biopsy will be used in all patients.
Ultrasound: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
          </group>
          <group group_id="O2">
            <title>Non-Ultrasound Guided Group</title>
            <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Receiving Diagnosis From Muscle Biopsy</title>
          <description>The rate of achieving a specific final diagnosis in ultrasound guided muscle biopsies vs. unguided biopsies will be examined.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Related to Muscle Biopsy</title>
        <description>Data will be examined to determine if ultrasound guidance reduces the rate of adverse events in muscle biopsies.</description>
        <time_frame>Patient involvement limited to the time of biopsy; Records analyzed up to 10 months after biopsy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrasound Guided Biopsy</title>
            <description>Ultrasound guided biopsy will be used in all patients.
Ultrasound: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
          </group>
          <group group_id="O2">
            <title>Non-Ultrasound Guided Group</title>
            <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Related to Muscle Biopsy</title>
          <description>Data will be examined to determine if ultrasound guidance reduces the rate of adverse events in muscle biopsies.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Times Biopsy Needle Was Inserted to Obtain Biopsy Tissue</title>
        <description>For &quot;core&quot; or &quot;needle&quot; biopsies, the physician passes the needle into the muscle until they feel that adequate tissue samples have been obtained. This outcome measure is the number of passes required in each study arm.</description>
        <time_frame>At time of biopsy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrasound Guided Biopsy</title>
            <description>Ultrasound guided biopsy will be used in all patients.
Ultrasound: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
          </group>
          <group group_id="O2">
            <title>Non-Ultrasound Guided Group</title>
            <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Times Biopsy Needle Was Inserted to Obtain Biopsy Tissue</title>
          <description>For &quot;core&quot; or &quot;needle&quot; biopsies, the physician passes the needle into the muscle until they feel that adequate tissue samples have been obtained. This outcome measure is the number of passes required in each study arm.</description>
          <units>needle passes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="0.756"/>
                    <measurement group_id="O2" value="2.5" spread="0.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Inadequate Biopsy Samples</title>
        <description>The presence of an inadequate sample was determined by the blinded pathologist reading the muscle biopsies. This reflects the sample having enough preserved muscle tissue for histologic analysis. It is separate from the number of participants receiving a diagnosis. A sample may be adequate, but non-diagnostic. Only one biopsy was performed in each patients, so the number of biopsies is the same as the number of participants.</description>
        <time_frame>At time of pathology review</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrasound Guided Biopsy</title>
            <description>Ultrasound guided biopsy will be used in all patients.
Ultrasound: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
          </group>
          <group group_id="O2">
            <title>Non-Ultrasound Guided Group</title>
            <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Inadequate Biopsy Samples</title>
          <description>The presence of an inadequate sample was determined by the blinded pathologist reading the muscle biopsies. This reflects the sample having enough preserved muscle tissue for histologic analysis. It is separate from the number of participants receiving a diagnosis. A sample may be adequate, but non-diagnostic. Only one biopsy was performed in each patients, so the number of biopsies is the same as the number of participants.</description>
          <units>Inadequate Biopsy Samples</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of consent to Six months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ultrasound Guided Biopsy</title>
          <description>Ultrasound guided biopsy will be used in all patients.
Ultrasound: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.</description>
        </group>
        <group group_id="E2">
          <title>Non-Ultrasound Guided Group</title>
          <description>The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Hobson-Webb</name_or_title>
      <organization>Duke University</organization>
      <phone>919-668-2277</phone>
      <email>lisa.hobsonwebb@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

